Bicycle Therapeutics Plc ADR [BCYC] stock is trading at $21.05, up 5.51%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCYC shares have gain 5.20% over the last week, with a monthly amount drifted -14.78%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] stock has seen the most recent analyst activity on November 08, 2024, when Stephens initiated its Equal-Weight rating and assigned the stock a price target of $25. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on September 06, 2024, and set its price target to $35. On August 07, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $28 on the stock. B. Riley Securities upgraded its rating to a Buy. Cowen initiated its recommendation with a Outperform. Barclays started tracking with a Overweight rating for this stock on July 28, 2022, and assigned it a price target of $30.
Bicycle Therapeutics Plc ADR [BCYC] stock has fluctuated between $14.39 and $28.67 over the past year. Currently, Wall Street analysts expect the stock to reach $43.67 within the next 12 months. Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] shares were valued at $21.05 at the most recent close of the market. An investor can expect a potential return of 107.46% based on the average BCYC price forecast.
Analyzing the BCYC fundamentals
Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] reported sales of 36.97M for the trailing twelve months, which represents a drop of -49.19%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -5.95%, Pretax Profit Margin comes in at -5.21%, and Net Profit Margin reading is -4.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.27 and Total Capital is -0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.17 points at the first support level, and at 19.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.61, and for the 2nd resistance point, it is at 22.17.
Ratios To Look Out For
For context, Bicycle Therapeutics Plc ADR’s Current Ratio is 17.13. Further, the Quick Ratio stands at 17.13, while the Cash Ratio is 15.79. Considering the valuation of this stock, the price to sales ratio is 39.30, the price to book ratio is 1.75.
Transactions by insiders
Recent insider trading involved Thompson Travis Alvin, CHIEF ACCOUNTING OFFICER, that happened on Nov 11 ’24 when 6256.0 shares were sold. Officer, Thompson Travis Alvin completed a deal on Nov 11 ’24 to buy 6256.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Lee Kevin sold 3212.0 shares on Oct 03 ’24.
